Technology | May 28, 2013

FDA Clears Sensus Healthcare Radiotherapy System to Treat Keloids

The SRT-100 is an option to treat non-melanoma skin cancer and keloids.

May 28, 2013 — Sensus Healthcare has received clearance from the U.S. Food and Drug Administration (FDA) to treat Keloids with the SRT-100. The SRT-100 is an alternative to surgery in treating non-melanoma skin cancer and now is approved to treat keloids caused by surgery or injury. Leading dermatologists and oncologists have found the SRT-100 superficial radiation therapy system to be a choice for their patients who are not good surgical candidates.  Sensus Healthcare has reintroduced superficial radiotherapy (SRT) to the global clinical community as a viable, safe, and cost-effective modality to treat non-melanoma skin cancers and keloids in hospitals and private practice settings.

"Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45 to 100 percent. Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences," said Mark S. Nestor, M.D., Ph.D., of the Center for Cosmetic Enhancement in Aventura, Fla.

"It is very fortunate that the FDA has approved the Sensus SRT-100, the first computerized, state-of-the-art, in-office SRT device for the treatment of recurrent keloid scars. Dermatologists now have a safe, effective in-office modality available to offer our keloid patients."

The SRT-100 has SharpBeam technology, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, Health Canada and SFDA cleared and is manufactured in the United States.

For more information: www.sensushealthcare.com 

Related Content

RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...